

Cipher Pharmaceuticals Inc.

Interim Condensed Consolidated Financial Statements

For the Three and Six Months Ended June 30, 2018

Unaudited

Cipher Pharmaceuticals Inc.
Interim Consolidated Statements of Financial Position

As at June 30, 2018, December 31, 2017 and January 1, 2017
(in thousands of United States dollars - unaudited)

| | | June 30, 2018 | December 31, 2017 | January 1, 2017 |
|---|---------|------------------|----------------------|--------------------|
| | Note | \$ | \$ | \$ |
| | | | Restated Note 2 | Restated Note 2 |
| ASSETS | | | | |
| Current assets | | | | |
| Cash | | 12,639 | 28,241 | 34,486 |
| Accounts receivable | | 12,464 | 21,906 | 14,644 |
| Inventory | 4 | 824 | 488 | 1,272 |
| Prepaid expenses and other assets | | 1,027 | 1,519 | 1,767 |
| Other receivable | 3 | 1,700 | 1,700 | - |
| | | 28,654 | 53,854 | 52,169 |
| Property and equipment, net | | 229 | 266 | 790 |
| Intangible assets, net | 4, 6, 7 | 13,460 | 5,400 | 17,582 |
| Goodwill | 4 | 15,706 | - | - |
| Deferred tax assets | 12 | 2,946 | 3,488 | 6,687 |
| Total assets | | 60,995 | 63,008 | 77,228 |
| LIABILITIES | | | | |
| Current liabilities | | | | |
| Accounts payable and accrued liabilities | 3, 4 | 13,534 | 18,705 | 16,003 |
| Contract liability | 3 | 1,017 | 1,651 | 4,769 |
| Current portion of credit facility | 5 | 8,065 | 6,664 | - |
| | | 22,616 | 27,020 | 20,772 |
| Senior secured notes | 5 | - | - | 36,377 |
| Credit facility | 5 | 13,418 | 11,456 | - |
| Derivative financial instrument | 5 | 107 | 549 | 583 |
| Other long term liabilities | 3 | 169 | 680 | 996 |
| Total liabilities | | 36,310 | 39,705 | 58,728 |
| SHAREHOLDERS' EQUITY | | | | |
| Share capital | | 18,241 | 18,020 | 16,192 |
| Contributed surplus | | 4,949 | 4,715 | 6,024 |
| Accumulated other comprehensive loss | | (9,514) | (9,514) | (9,514) |
| Retained earnings | | 11,009 | 10,082 | 5,798 |
| Total shareholders' equity | | 24,685 | 23,303 | 18,500 |
| Total liabilities and shareholders' equity | | 60,995 | 63,008 | 77,228 |
| Commitments and Contingencies | 14 | | | |

The accompanying notes are an integral part of these unaudited interim consolidated financial statements

Cipher Pharmaceuticals Inc.

Interim Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)

Three and six months ended June 30, 2018 and 2017

(in thousands of United States dollars, except per share data - unaudited)

| | Note | Three months ended June 30 | | Six months ended June 30 | |
|---|------|-------------------------------|--------------------|-----------------------------|--------------------|
| | | 2018 | 2017 | 2018 | 2017 |
| | | \$ | \$ | \$ | \$ |
| | | | Restated Note 2 | | Restated Note 2 |
| Revenues | | | | | |
| Licensing revenue | 9 | 5,241 | 8,582 | 8,001 | 15,432 |
| Product revenue | | 1,716 | 1,288 | 3,529 | 2,540 |
| Net revenues | | 6,957 | 9,870 | 11,530 | 17,972 |
| Operating expenses | | | | | |
| Cost of products sold | | 563 | 454 | 1,059 | 907 |
| Research and development | | 146 | 58 | 190 | 169 |
| Selling, general and administrative | 10 | 3,399 | 3,018 | 6,808 | 5,911 |
| Impairment of intangible assets | | - | - | 1,832 | - |
| Total operating expenses | | 4,108 | 3,530 | 9,889 | 6,987 |
| Other expenses (income) | | | | | |
| Interest expense | 5 | 215 | 652 | 397 | 2,076 |
| Change in fair value of derivative financial instrument | 5 | (121) | 92 | (442) | (6) |
| Interest income | | (62) | (2) | (114) | (5) |
| Loss on debt extinguishment | 5 | - | - | - | 5,223 |
| Foreign exchange loss (gain) | | (25) | (31) | 50 | (59) |
| Total other expenses (income) | | 7 | 711 | (109) | 7,229 |
| Income before income taxes from continuing operations | | 2,842 | 5,629 | 1,750 | 3,756 |
| Current income tax expense | | 294 | - | 244 | - |
| Deferred income tax expense | 12 | 633 | 1,225 | 542 | 944 |
| Total income tax expense | | 927 | 1,225 | 786 | 944 |
| Income and comprehensive income from continuing operations | | 1,915 | 4,404 | 964 | 2,812 |
| Income (loss) and comprehensive income (loss) from discontinued operations | 3 | 213 | (3,268) | (37) | (5,030) |
| Income (loss) and comprehensive income (loss) for the period | | 2,128 | 1,136 | 927 | (2,218) |
| Income from continuing operations per common share | 13 | | | | |
| Basic | | 0.07 | 0.16 | 0.04 | 0.11 |
| Diluted | | 0.07 | 0.16 | 0.04 | 0.11 |
| Income (loss) from discontinued operations per common share | 13 | | | | |
| Basic | | 0.01 | (0.12) | (0.00) | (0.19) |
| Diluted | | 0.01 | (0.12) | (0.00) | (0.19) |
| Income (loss) and comprehensive income (loss) per common share | 13 | | | | |
| Basic | | 0.08 | 0.04 | 0.03 | (0.08) |
| Diluted | | 0.08 | 0.04 | 0.03 | (0.08) |

The accompanying notes are an integral part of these unaudited interim consolidated financial statements

Cipher Pharmaceuticals Inc.
Interim Consolidated Statements of Changes in Shareholders' Equity

Six month ended June 30, 2018 and 2017
(in thousands of United States dollars - unaudited)

| | Note | Share Capital | Contributed Surplus | Other Comprehensive Loss | Retained Earnings | Total Shareholders' Equity |
|--|------|---------------|---------------------|--------------------------|-------------------|----------------------------|
| | | 000's | \$ | \$ | \$ | \$ |
| Balance, January 1, 2018 | | 26,721 | 18,020 | 4,715 | 10,082 | 23,303 |
| Income for the period | | - | - | - | 927 | 927 |
| Exercise of stock options | 8 | 1 | 2 | (1) | - | 1 |
| Shares issued under the share purchase plan | 8 | 21 | 60 | - | - | 60 |
| Shares issued under the Restricted and Performance Share Unit plan | | 36 | 159 | (159) | - | - |
| Share-based compensation expense | 8 | - | - | 394 | - | 394 |
| Balance, June 30, 2018 | | 26,779 | 18,241 | 4,949 | 11,009 | 24,685 |
| Balance, January 1, 2017 | | 26,313 | 16,192 | 6,024 | 5,798 | 18,500 |
| Loss for the period | 2 | - | - | - | (2,218) | (2,218) |
| Exercise of stock options | 8 | 214 | 1,072 | (635) | - | 437 |
| Shares issued under the share purchase plan | 8 | 18 | 65 | - | - | 65 |
| Shares issued under the Restricted and Performance Share Unit plan | | 73 | 377 | (377) | - | - |
| Share-based compensation expense | 8 | - | - | (272) | - | (272) |
| Balance, June 30, 2017 | | 26,618 | 17,706 | 4,740 | 3,580 | 16,512 |

The accompanying notes are an integral part of these unaudited interim consolidated financial statements

Cipher Pharmaceuticals Inc.
Interim Consolidated Statements of Cash Flows

Six months period ended June 30, 2018 and 2017
(in thousands of United States dollars - unaudited)

| | Note | 2018 | 2017 |
|--|----------|-----------------|-----------------|
| | | \$ | \$ |
| Cash provided by (used in) | | | |
| Operating activities | | | |
| Income for the period from continuing operations | | 964 | 2,812 |
| Items not affecting cash: | | | |
| Depreciation of property and equipment | | 75 | 63 |
| Amortization of intangible assets | | 316 | 419 |
| Impairment of intangible assets | 7 | 1,832 | - |
| Share-based compensation | | 403 | 238 |
| Foreign exchange loss on cash | | 75 | 17 |
| Change in fair value of derivative | | (442) | (6) |
| Loss on debt extinguishment | | - | 5,223 |
| Interest on long term debt | | 397 | 2,076 |
| Deferred income taxes | | 542 | 945 |
| Changes in non-cash operating items: | | | |
| Accounts receivable | | 9,442 | (5,619) |
| Inventory | | (328) | (124) |
| Prepaid expenses and other assets | | 354 | 386 |
| Accounts payable and accrued liabilities | | (4,536) | (831) |
| Net cash provided by operating activities | | 9,094 | 5,599 |
| Investing activities | | | |
| Purchase of property and equipment | | - | (38) |
| Milestone payments related to intangible assets | | - | (148) |
| Acquisition of intangible assets | 6 | (6,000) | - |
| Acquisition of Cardiome Pharma Corp. | 4 | (19,141) | - |
| Net cash received from disposal of assets | 3 | - | 7,619 |
| Net cash provided in (used in) investing activities | | (25,141) | 7,433 |
| Financing activities | | | |
| Interest payments | | (260) | (1,565) |
| Repayment of credit facility | | (1,666) | (20,000) |
| Proceeds from credit facility | 5 | 5,000 | - |
| Financing costs | 5 | (108) | (2,500) |
| Payment of finance lease liability | | (21) | (19) |
| Proceeds from shares issued under the share purchase plan | | 51 | 55 |
| Proceeds from exercise of stock options | | 1 | 437 |
| Net cash provided in (used in) financing activities | | 2,997 | (23,592) |
| Cash used in discontinued operations | 3 | (2,477) | (4,246) |
| Decrease in cash | | (15,527) | (14,806) |
| Impact of foreign exchange on cash | | (75) | (17) |
| Cash, beginning of period | | 28,241 | 34,486 |
| Cash, end of period | | 12,639 | 19,663 |

The accompanying notes are an integral part of these unaudited interim consolidated financial statements

Cipher Pharmaceuticals Inc.

Notes to Interim Condensed Consolidated Financial Statements

June 30, 2018

(in thousands of United States dollars, except per share amounts - unaudited)

1. NATURE OF OPERATIONS

Cipher Pharmaceuticals Inc. ("Cipher") and its subsidiaries (together the "Company") is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada and the United States ("U.S.") or indirectly through partners in the U.S., Canada and Latin America. The Company is building its business through product licensing and acquisitions. Cipher was incorporated under the Business Corporations Act of Ontario on January 9, 2004 and is located at 2345 Argenta Road, Mississauga, Ontario.

On May 1, 2017, the Company, through its wholly owned subsidiary Cipher Pharmaceuticals US LLC ("Cipher U.S.") sold substantially all of the assets of its U.S. segment. The Company no longer directly markets products in the U.S.

2. BASIS OF PREPARATION

These interim condensed consolidated financial statements have been prepared in accordance with International Accounting Standard ("IAS") 34, *Interim Financial Reporting*. The disclosures contained in these interim condensed consolidated financial statements do not include all of the requirements of International Financial Reporting Standards ("IFRS") for annual financial statements. The interim condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements for the year ended December 31, 2017, which have been prepared in accordance with IFRS, as issued by the International Accounting Standards Board ("IASB") and are available on SEDAR at www.sedar.com. The interim condensed consolidated financial statements are based on accounting policies as described in the 2017 annual consolidated financial statements except for that effective January 1, 2018, the Company implemented IFRS 15, *Revenue from Contracts with Customers* and IFRS 9, *Financial Instruments*.

The Board of Directors approved these interim condensed consolidated financial statements on August 9, 2018.

Reclassification of comparative period presentation

Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations, only classifications of certain operating expenses. Specifically, product distribution costs previously recognized in selling, general and administrative ("SG&A") costs have been reclassified to cost of products sold.

Discontinued operations

The Company reports financial results for discontinued operations separately from continuing operations to distinguish the financial impact of disposal transactions from ongoing operations. Discontinued operations reporting occurs when the disposal of a component or a group of components of the Company represents a strategic shift that will have major impact on the Company's operations and financial results, and where the operations and cash flows can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the Company.

The results of discontinued operations are excluded from both continuing operations and business segment information in the interim condensed consolidated financial statements and the notes to the interim condensed consolidated financial statements, unless otherwise noted, and are presented net of tax in the statement of income (loss) and comprehensive income (loss) for the current and comparative periods. Refer to Note 3 Discontinued Operations for further information regarding the facts and circumstances which gave rise to the Company's discontinued operations.

Business combinations

The acquisition during the three months ended June 30, 2018 has been accounted for as a business combination using the acquisition method. The consideration transferred in a business combination is measured at fair value at the date of acquisition. Acquisition-related transaction costs are recognized in the interim condensed consolidated statements of income (loss) and comprehensive income (loss) as incurred. At the acquisition date, the identifiable assets acquired, and the liabilities assumed are initially recognized at their fair value. Goodwill is measured as the excess of the sum of the consideration transferred and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the acquisition-date amounts of the identifiable assets acquired and liabilities assumed. When the consideration transferred by the Company in a business combination includes assets or liabilities resulting from a contingent consideration arrangement, the contingent consideration is measured at its acquisition-date fair value and included as part of the consideration transferred in a business combination. Changes in the fair value of the contingent consideration that qualify as measurement period adjustments are adjusted retrospectively, with corresponding adjustments against goodwill. Changes in fair value that are not considered measurement adjustments are recognized in the interim condensed consolidated statements of income (loss) and comprehensive income (loss). Measurement period adjustments are adjustments that arise from additional information obtained during the 'measurement period' (which cannot exceed one year from the acquisition date) about facts and circumstances that existed

Cipher Pharmaceuticals Inc.

Notes to Interim Condensed Consolidated Financial Statements

June 30, 2018

(in thousands of United States dollars, except per share amounts - unaudited)

at the acquisition date. Other than measurement period adjustments, contingent consideration that is classified as a financial asset or a financial liability is remeasured at subsequent reporting dates, with the corresponding gain or loss being recognized in the interim condensed consolidated statements of income (loss) and comprehensive income (loss).

The Company assesses whether an acquisition should be accounted for as an asset acquisition or business combination under IFRS 3, *Business Combinations* ("IFRS 3"). This assessment requires management to make judgements on whether the assets acquired and liabilities assumed constitute a business as defined in IFRS 3 and if the integrated set of activities, including inputs, processes acquired, is capable of being conducted and managed as a business and the Company obtains control of the business. The Company's acquisition of Cardiome was accounted for as a business combination.

Goodwill

Goodwill arises on business combinations and represents the excess of the consideration transferred over the fair value of the identifiable net assets acquired. For the purpose of impairment testing, goodwill acquired in a business combination is allocated to each of the CGUs, or groups of CGUs, that is expected to benefit from the synergies of the combination. Each unit or group of units to which the goodwill is allocated represents the lowest level within the entity at which the goodwill is monitored for internal management purposes. Goodwill is monitored at the operating segment level. Goodwill impairment reviews are undertaken annually or more frequently if events or changes in circumstances indicate a potential impairment. The carrying value of the groups of CGUs which contains goodwill is compared to the recoverable amount, which is the higher of value in use and the fair value less costs of disposal. Any impairment is recognized immediately as an expense and is not subsequently reversed.

Fair value of financial instruments

Fair value is defined as the price that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The best evidence of fair value is quoted bid or ask prices in an active market. Quoted prices are not always available for over-the-counter transactions, as well as transactions in inactive or illiquid markets. In these instances, pricing models, normally with observable market based inputs, are used to estimate fair value. Financial instruments traded in a less active market have been valued using indicative market prices, present value or other valuation techniques. Where financial instruments trade in inactive markets or when using models where observable parameters do not exist, greater management judgement is required for valuation purposes. In addition, the calculation of estimated fair value is based on market conditions at a specific point in time and therefore may not be reflective of future fair values.

As at June 30, 2018, the Company's financial instruments consisted of cash, accounts receivable, accounts payable and accrued liabilities, other long-term liabilities, the credit facility and a derivative financial instrument. The derivative financial instrument is measured at fair value with any changes recognized through the consolidated statements of income (loss) and comprehensive income (loss) and is classified as Level 2 (as defined under IFRS). Cash, accounts receivable, accounts payable and accrued liabilities and other long-term liabilities are measured at amortized cost and their fair values approximate carrying values.

The credit facility is measured at amortized cost. At June 30, 2018, the fair value of the credit facility is approximately \$21,483. The fair value is based on cash flows discounted using a rate based on the borrowing rate.

Changes in accounting policies

IFRS 9, *Financial Instruments* – The Company adopted this standard on January 1, 2018. No adjustment to the comparative period was required. Currently, the Company's financial instruments are cash, accounts receivable, accounts payable and accrued liabilities, other long-term liabilities and its credit facility. With respect to its accounts receivable, historically, the Company's credit losses have been negligible as are past due amounts and therefore no adjustments relating to credit losses were required in the current or comparative period. The Company has adopted the simplified approach to accounting for credit losses.

IFRS 15, *Revenue from Contracts with Customers* – The Company adopted this standard on January 1, 2018 using the full retrospective approach, resulting in a restatement of the 2017 comparative period. No practical expedients have been used.

Cipher Pharmaceuticals Inc.

Notes to Interim Condensed Consolidated Financial Statements

June 30, 2018

(in thousands of United States dollars, except per share amounts - unaudited)

The impact to the comparative interim consolidated statements of financial position is as follows:

| | Dec 31, 2017 as presented | Adjustment | Dec 31, 2017 restated |
|--|------------------------------|------------|--------------------------|
| | \$ | \$ | \$ |
| Assets: | | | |
| Deferred tax asset | 3,610 | (122) | 3,488 |
| Total assets | 63,130 | (122) | 63,008 |
| Liabilities: | | | |
| Current portion of deferred revenue | 177 | (177) | - |
| Deferred revenue | 312 | (312) | - |
| Total liabilities | 40,194 | (489) | 39,705 |
| Retained earnings | 9,715 | 367 | 10,082 |
| Total liabilities and shareholders' equity | 63,130 | (122) | 63,008 |

The impact to the comparative interim consolidated statement of income (loss) and comprehensive income (loss) for the three months ended June 30 is as follows:

| | June 30, 2017 as presented | Adjustment | June 30, 2017 restated |
|--|-------------------------------|------------|---------------------------|
| | \$ | \$ | \$ |
| Licensing revenue | 8,627 | (45) | 8,582 |
| Net revenue | 9,915 | (45) | 9,870 |
| Deferred income tax recovery | 1,237 | (12) | 1,225 |
| Income and comprehensive income from continuing operations | 4,437 | (33) | 4,404 |
| Income and comprehensive income for the period | 1,169 | (33) | 1,136 |

The impact to the comparative interim consolidated statement of income (loss) and comprehensive income (loss) for the six months ended June 30 is as follows:

| | June 30, 2017 as presented | Adjustment | June 30, 2017 restated |
|--|-------------------------------|------------|---------------------------|
| | \$ | \$ | \$ |
| Licensing revenue | 15,518 | (86) | 15,432 |
| Net revenue | 18,058 | (86) | 17,972 |
| Deferred income tax recovery | 967 | (23) | 944 |
| Income and comprehensive income from continuing operations | 2,875 | (63) | 2,812 |
| Loss and comprehensive loss for the period | (2,155) | (63) | (2,218) |

Licensing revenue

Licensing revenue is comprised of upfront payments, pre-commercialization milestones, post-commercialization milestones, royalties and product supply fees. Pre-commercialization milestones, not representing a financing component is deferred and recognized on a straight-line basis over the estimated term that the Company provides services. Post-commercialization milestones, such as sales targets are recognized as revenue when the underlying condition is achieved and is unconditional on any further performance. Otherwise, these milestone payments are recognized as revenue over the remaining term of the underlying agreement or the estimated service term for which the Company maintains contractual obligations. Royalty revenue is recognized in the period in which the Company earns the royalty. Licensing partners report royalty revenue monthly and remit payment within 30 days after each quarter end. Licensing product sales are recognized when the finished products are shipped from Galephar to the Company's licensing partners, at which time control is transferred. Upfront payments, pre-and post-commercialization milestones, royalties and product supply fees represent the Company's 50% share of revenue from agreements with licensing partners, after amounts due to Galephar or other third parties.

Deferred revenue – Deferred revenue represented amounts paid by the Company's licensing partners upon achievement of certain milestones and were amortized over a relevant period. These were determined to be point in time recognition to coincide with the timing of when control was transferred. Therefore, licensing revenue for the three and six months ended June 30, 2017 was reduced by \$45 and \$86, respectively. Additionally, the current and long-term portion of the deferred revenue on the consolidated statements of financial

Cipher Pharmaceuticals Inc.

Notes to Interim Condensed Consolidated Financial Statements

June 30, 2018

(in thousands of United States dollars, except per share amounts - unaudited)

position were adjusted to opening retained earnings to reflect recognition at the point in time when control was transferred. Accordingly, the Company has restated the consolidated statements of financial position.

Accounting for costs to fulfil a contract – The Company may incur costs to fulfil a contract that are directly related. While there were no such costs incurred in the current period and comparative period, such amounts will be capitalized to prepaids and other assets in the consolidated statements of financial position. The Company has determined that costs to fulfill contracts entered into prior to January 1, 2017 are not significant to the consolidated statements of financial position and statements of income (loss) and comprehensive income (loss).

Financing component – Agreements entered into with licensing partners often include an upfront fee upon execution of the agreement. If considered significant in the context of the arrangement, these upfront fees are accounted for as a financing component.

Product revenue

Performance obligations for product sales is primarily satisfied upon delivery of product to the Company's customers, however in a few instances it may be upon shipment. The transaction price is based on list prices that are published annually. Revenue is recorded on a net basis, representing the amounts receivable from customers after the deduction for discounts, returns and early payment discounts. The methodology and assumptions used to estimate discounts, returns and early payments discounts are monitored and adjusted in light of contractual and historical information. Invoices are generated at the time of product shipment and are payable in 30 days.

Contract liability – The Company estimates a returns provision upon the sale of its commercial products, which is recorded in contract liability. Commercial products may be returned upon expiry or otherwise in unsalable condition when received by its customers.

The provision for returns is a complex estimate used in the recognition of revenue. The Company has a returns policy that allows wholesalers to return product within a specified period prior to and subsequent to the expiration date. Provisions for returns are recognized in the period in which the underlying sales are recognized, as a reduction of product sales revenue. The Company estimates provisions for returns based upon historical experience if applicable, representing management's best estimate. While such experience has allowed for reasonable estimations in the past, history may not always be an accurate indicator of future returns. The Company continually monitors provisions for returns and adjusts when it believes that actual product returns may differ from established reserves. Given that the Company's launch of three of its five products have occurred within the past 2 years, few products have entered the returns window for expired goods and therefore the Company does not have historical information as a basis for estimating its returns provision.

Accounting standards issued but not yet adopted

IFRS 16, Leases: In January 2016, the IASB published a new standard, IFRS 16. The new standard will eliminate the distinction between operating and finance leases and will bring most leases on the balance sheet for lessees. This standard is effective for annual reporting periods beginning on or after January 1, 2019. The Company has assessed that all its leases, except for its low value leases will be recorded on the consolidated statements of financial position.

International Financial Reporting Interpretations Committee (IFRIC), Uncertainty over Income Tax Treatments (IFRIC 23): In June 2017, the IASB issued IFRIC 23, Uncertainty over Income Tax Treatments, with a mandatory effective date of January 1, 2019. The interpretations provide guidance on how to value uncertain income tax positions based on the probability of whether the relevant tax authorities will accept the Company's tax treatments. A company is to assume that a taxation authority with the right to examine any amounts reported to it will examine those amounts and will have full knowledge of all relevant information when doing so. IFRIC 23 is to be applied by recognizing the cumulative effect of initially applying these guidelines in opening retained earnings without adjusting comparative information. The extent of the impact of the adoption of IFRIC 23 has not yet been determined.

Other accounting standards or amendments to existing accounting standards that have been issued, but have future effective dates, are either not applicable or are not expected to have a significant impact on the Company's consolidated financial statements.

3. DISCONTINUED OPERATIONS

On May 1, 2017, the Company entered into an Asset Purchase Agreement (the "U.S. APA") and completed the sale of substantially all of the assets comprising the U.S. segment. In accordance with the terms of the U.S. APA, the purchase price of \$13,600 was subject to customary working capital adjustments and other transferred liabilities as defined in the U.S. APA. The Company retained responsibility for certain liabilities and commitments. On closing, the Company received \$7,619 in cash.

The terms of the U.S. APA, include a hold back of \$1,700, which will be settled 18 months from the date of closing and an additional regulatory milestone of up to \$750 if certain predefined conditions are achieved. The hold back of \$1,700 is classified as other receivable

Cipher Pharmaceuticals Inc.

Notes to Interim Condensed Consolidated Financial Statements

June 30, 2018

(in thousands of United States dollars, except per share amounts - unaudited)

in the consolidated statements of financial position. In the fourth quarter of 2017, the regulatory milestone was achieved and the Company received an additional \$740, net of administrative costs. The total cash consideration received to date is \$9,339.

The following table summarizes the balances retained by the Company as at June 30, 2018, which are included in the consolidated statements of financial position:

| | \$ |
|--|--------------|
| Accounts payable and accrued liabilities | 1,266 |
| Contract liability | 1,017 |
| Other long-term liabilities | 94 |
| Total | 2,377 |

Accounts payable and accrued liabilities and other long-term liabilities includes provisions for onerous contracts and amounts due to former customers for product returns and vendors. The contract liability reflects future product returns that were retained by the Company.

A reconciliation of the major classes of line items constituting income (loss) from discontinued operations, net of tax, as presented in the consolidated statements of income (loss) and comprehensive income (loss) is as follows:

| | Three months ended June 30, 2018 | Three months ended June 30, 2017 | Six months ended June 30, 2018 | Six months ended June 30, 2017 |
|---|---|--|---|--------------------------------------|
| | \$ | \$ | \$ | \$ |
| Net revenues | 157 | 604 | 22 | 2,931 |
| Operating expenses (income) | (56) | 4,237 | 59 | 8,326 |
| Income (loss) before gain on disposal | 213 | (3,633) | (37) | (5,395) |
| Gain on disposal | - | 365 | - | 365 |
| Income (loss) before income taxes | 213 | (3,268) | (37) | (5,030) |
| Income taxes | - | - | - | - |
| Income (loss) and comprehensive income (loss) from discontinued operations | 213 | (3,268) | (37) | (5,030) |

Disclosures with respect to the consolidated statements of cash flows are as follows:

| | Six months ended June 30, 2018 | Six months ended June 30, 2017 |
|---|---|-----------------------------------|
| | \$ | \$ |
| Net cash flows attributable to: | | |
| Operating activities | (2,477) | (4,238) |
| Investing activities | - | (8) |
| Cash used in discontinued operations | (2,477) | (4,246) |

4. ACQUISITION OF CARDIOME PHARMA CORP.

On May 15, 2018, the Company acquired the Canadian business portfolio of Cardiome Pharma Corp. ("Cardiome") by acquiring all of the issued and outstanding common shares of Cardiome (the "Acquisition") pursuant to the terms and conditions of a definitive arrangement agreement (the "Arrangement Agreement") entered into among Cipher, Cardiome and Correvio Pharma Corp. ("Correvio") on March 19, 2018. Upon completion of the acquisition, Cardiome become a wholly owned subsidiary of the Company. The Canadian business portfolio acquired by the Company includes commercial and pipeline hospital products administered in the acute care setting. The Company acquired Cardiome as part of its ongoing efforts to diversify its product base.

The total purchase price of CDN\$25,500 (\$19,922) of which CDN\$24,500 (\$19,141) was paid in cash on closing and a holdback of CDN\$1,000 (\$781) is payable in four equal installments quarterly from the date of the agreement. The holdback is recognized in

Cipher Pharmaceuticals Inc.
Notes to Interim Condensed Consolidated Financial Statements
June 30, 2018
(in thousands of United States dollars, except per share amounts - unaudited)

accounts payable and accrued liabilities on the consolidated statements of financial position. Total transaction costs incurred were \$589, which are recorded in SG&A in the consolidated statements of income (loss) and comprehensive income (loss).

The following table presents the preliminary fair value of the assets acquired and liabilities assumed at the date of the acquisition.

| | \$ |
|-------------------|--------|
| Purchase price | 19,922 |
| Inventory | 8 |
| Intangible assets | 4,208 |
| Goodwill | 15,706 |

Goodwill represents the Cardiome's tax loss carry forwards, investment tax credits and scientific research and experimental development credits that Cipher intends to use as a result of carrying on the former Cardiome business. The goodwill recognized is expected to be deductible for income tax purposes. The final purchase price allocation will be determined when Cipher has completed the detailed valuations and necessary calculations and could differ materially from the preliminary purchase price. The final purchase price allocation may include (1) changes in fair value of intangible assets comprised of product and licensing rights (2) recognition of deferred tax assets or deferred tax liabilities and (3) the resultant changes to the amount recognized as goodwill.

Intangible assets represent product and licensing rights and licensing rights to four products, where the Company has exclusivity in Canada. An assigned licensing right includes a milestone payment of \$1,000 upon launching the product and revenue milestones upon achieving a specified level of sales in a calendar year.

Had Cardiome been consolidated from January 1, 2017, the consolidated statements of income (loss) and comprehensive income (loss) would show pro forma revenue of \$40,296 and income and comprehensive income of \$3,281. The pro forma adjustments also include the retrospective adjustment of adopting IFRS 15, *Revenue from Contracts with Customers*, which reduces revenue by \$177 and income and comprehensive income by \$130.

The impact of consolidating Cardiome for the three months ended March 31, 2018 is pro forma revenue of \$4,611 and loss and comprehensive loss of \$1,384.

5. SENIOR SECURED NOTES AND CREDIT FACILITY

On March 31, 2017, the Company entered into its sixth amendment to the Securities Purchase Agreement (the "Amendment") with its lender to amend the terms of the Senior Secured Notes ("Notes") under the original Securities Purchase Agreement (the "Original SPA"), dated April 13, 2015. In connection with the Amendment, the Company prepaid \$20,000 of the outstanding Notes balance on April 5, 2017. The Amendment was accounted for as an extinguishment, as the terms of the amended agreement were substantially different. Therefore, the unamortized costs related to the Notes were accelerated and recognized as part of the loss on extinguishment. In addition, on April 5, 2017, the Company paid the 5% borrowing fee of \$1,000, the 5% prepayment penalty of \$1,000 and an amendment fee of \$500. In consideration for the prepayment, the lender modified the financial covenants and removed its security interest in the U.S. segment assets.

On November 3, 2017, the Company entered into a credit agreement, with a Canadian lender to extinguish its existing Notes and replace with a credit facility. In connection with the credit agreement, the Company used the proceeds of \$20,000 to fully extinguish the remaining balance of the Notes. Pursuant to the Original SPA, the Company paid a prepayment penalty of \$1,000 and a borrowing fee of \$1,000. The credit facility has a three-year term, carrying an interest rate of LIBOR plus an applicable margin ranging from 1.5% - 2.5% based on the total debt to EBITDA ratio, as defined in the credit agreement. Principal and interest payments are payable quarterly in arrears. The credit facility also carries an accordion feature that allows for an additional \$10,000 of capacity, subject to customary terms and conditions. The Company is subject to certain financial and non-financial covenants, including total debt to EBITDA ratio, minimum fixed charge coverage ratio and minimum shareholders' equity as defined per the credit agreement. The credit facility is secured by the assets of the Company. The interest rate applicable in the second quarter was approximately 3.53%. The effective interest rate was 3.60%.

On May 15, 2018, concurrent with the acquisition of Cardiome, the Company drew \$5,000 from its existing credit facility. Net of transaction costs of \$108, the amount recorded to the consolidated statement of financial position was \$4,892. As a result, the scheduled quarterly payments increased from \$1,666 to \$2,000, however both the principal and interest payments due on June

Cipher Pharmaceuticals Inc.

Notes to Interim Condensed Consolidated Financial Statements

June 30, 2018

(in thousands of United States dollars, except per share amounts - unaudited)

30, 2018 were waived and is payable upon maturity. There was no corresponding change in the interest rate terms or term of the credit facility. As part of the amendment, the accordion was reset to \$10,000.

The following is the continuity of the credit facility from January 1, 2018 to June 30, 2018:

| | \$ |
|-------------------------------|---------------|
| Balance, January 1, 2018 | 18,120 |
| Interest expense | 146 |
| Interest paid | (146) |
| Imputed interest accretion | 36 |
| Repayment | (1,666) |
| Balance, March 31, 2018 | 16,490 |
| Proceeds, net | 4,892 |
| Interest expense | 181 |
| Interest paid | (114) |
| Imputed interest accretion | 34 |
| Balance, June 30, 2018 | 21,483 |
| Current portion | 8,065 |
| Long term portion | 13,418 |

The following is the continuity of the Notes from January 1, 2017 until extinguishment on November 3, 2017.

| | \$ |
|----------------------------|----------|
| Balance, January 1, 2017 | 36,377 |
| Interest expense | 2,282 |
| Interest paid | (2,282) |
| Prepayment penalty | 1,000 |
| Imputed interest accretion | 1,900 |
| Loss on extinguishment | 5,223 |
| Repayment | (44,500) |
| Balance, December 31, 2017 | - |

Derivative financial instrument

Under the terms of the Original SPA, the Company issued 600,000 common share purchase warrants with an option for a cashless exercise in which the settlement price caused the conversion ratio to be variable. Accordingly, the warrants are classified as a financial liability. Gains and losses on re-measurement are presented separately in the consolidated statements of income (loss) and comprehensive income (loss). The exercise price of the warrants is \$9.22 (equal to the five day volume-weighted average price on the Toronto Stock Exchange prior to closing, converted to U.S. dollars) and expire seven years from the date of issuance. A pricing model with observable market-based inputs was used to estimate the fair value of the warrants issued. The estimated fair value of the warrants as at June 30, 2018, March 31, 2018 and December 31, 2017 were \$107, \$228 and \$549, respectively.

The variables used to compute the fair value as at June 30, 2018, March 31, 2018 and December 31, 2017 as follows:

| | June 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
|---------------|------------------|--------------|--------------|
| Share price | \$2.22 | \$3.26 | \$3.91 |
| Expected life | 3.8 years | 4.0 years | 4.2 years |
| Volatility | 52.5% | 50.5% | 56.4% |

6. INTANGIBLE ASSETS

On February 27, 2018, the Company acquired the exclusive Canadian rights to market, distribute and sell Trulance®, a U.S. Food and Drug Administration ("FDA") approved product. In connection with the acquisition, the Company paid an upfront payment of \$5,000 upon execution of the agreement. The transaction includes a regulatory milestone payment of \$750 and royalties on net product sales in Canada.

Cipher Pharmaceuticals Inc.

Notes to Interim Condensed Consolidated Financial Statements

June 30, 2018

(in thousands of United States dollars, except per share amounts - unaudited)

On April 5, 2018, the Company acquired the exclusive Canadian rights to distribute and commercialize A-101. A-101 is an FDA approved topical product. Under the terms of the licensing agreement, the Company paid an upfront payment of \$1,000 and upon achievement of certain milestone events, will pay additional regulatory and commercial milestone payments of up to \$2,750, as well as royalties from net product sales in Canada.

| | Licensing and product rights |
|--|---|
| Cost | \$ |
| Balance, January 1, 2017 | 55,850 |
| Additions | 148 |
| Impairment (note 7) | (698) |
| Disposal of U.S. segment | (41,919) |
| Balance, January 1, 2018 | 13,381 |
| Additions | 10,208 |
| Impairment (note 7) | (2,792) |
| Balance, June 30, 2018 | 20,797 |
| Accumulated amortization and impairment | |
| Balance, January 1, 2017 | 38,268 |
| Amortization | 831 |
| Impairment (note 7) | (137) |
| Disposal of U.S. segment | (30,981) |
| Balance, January 1, 2018 | 7,981 |
| Amortization | 316 |
| Impairment (note 7) | (960) |
| Balance, June 30, 2018 | 7,337 |
| Net book value | |
| As at January 1, 2018 | 5,400 |
| As at June 30, 2018 | 13,460 |

7. IMPAIRMENT OF INTANGIBLE ASSETS

During the first quarter of 2018, the Company re-assessed its efforts to out license its Astion assets acquired in 2015 and decided not to continue to actively pursue partners for Dermadexin and Pruridexin products in this portfolio. Accordingly, the Company wrote off the net book value of these assets in the amount of \$1,832 in operating expenses in the consolidated statements of income (loss) and comprehensive income (loss).

In 2017, the Company completed its assessment of the Melanovus oncology assets acquired in 2014 and decided not to continue with this program. The Company provided to the seller a notice of termination in the fourth quarter of 2017 and after completion of the 90-day notice period, the agreement was terminated. Accordingly, the Company wrote off the net book value of these assets in the amount of \$561 in 2017.

8. SHARE CAPITAL

Authorized share capital

The authorized share capital consists of an unlimited number of preference shares, issuable in series, and an unlimited number of voting common shares, with no par value.

The Company has three stock-based compensation plans: the Stock Option Plan ("SOP"), the Employee and Director Share Purchase Plan ("ESPP") and the Restricted Share Units and Performance Share Units ("PR Plan"). Full descriptions of the three stock-based compensation plans are included in Note 13 "Share Capital" to the Company's annual consolidated financial statements for the year ended December 31, 2017.

Cipher Pharmaceuticals Inc.

Notes to Interim Condensed Consolidated Financial Statements

June 30, 2018

(in thousands of United States dollars, except per share amounts - unaudited)

Share purchase plan

The Company's ESPP allows employees and directors to share in the growth of the Company through share ownership. Through the ESPP, employees and directors may contribute amounts to purchase shares of the Company at a 15% discount from the prevailing trading price. Plan members must hold their shares for a period of at least six months before they can be sold. During the three months ended June 30, 2018, 11,587 shares were issued under the ESPP (three months ended June 30, 2017 – 7,772). Included in share-based compensation expense is \$5 (three months ended June 30, 2017 – \$4), which is the discount on the shares issued during the period. During the six months ended June 30, 2018, 20,762 shares were issued under the ESPP (six months ended June 30, 2017 – 18,240). Included in share-based compensation expense is \$9 (six months ended June 30, 2017 – \$10).

Stock option plan

The following is a summary of the changes in the stock options outstanding from January 1, 2018 to June 30, 2018:

| | Number of options (in 000's) | Weighted average exercise price (CDN\$) |
|-------------------------------------|------------------------------------|---|
| Balance, January 1, 2018 | 603 | 5.80 |
| Granted during the period | 469 | 3.53 |
| Exercised during the period | (1) | 2.32 |
| Forfeited/expired during the period | (89) | 8.36 |
| Balance, June 30, 2018 | 982 | 4.49 |

As at June 30, 2018, 144,022 options were fully vested and exercisable (June 30, 2017 – 524,249).

In Q1 2018, the Company granted 469,468 stock options under the SOP. The options vest over a four-year period from the grant date, at a rate of 25% per year and expire seven years from the day of grant. The expected volatility is based on the Company's historical volatility over a comparable period based on expected life. There is no expected dividend. The exercise price and Black Scholes assumptions are as follows:

| Grant date | Number granted | Exercise price (CDN\$) | Black Scholes value (CDN\$) | Risk-free interest rate | Expected life | Expected volatility |
|----------------|-------------------|---------------------------|--------------------------------|----------------------------|------------------|------------------------|
| March 22, 2018 | 469,468 | \$3.53 | \$1.55 | 1.94% | 4.9 years | 48.2% |

The following information relates to stock options that were outstanding as at June 30, 2018:

| Range of exercise prices (CDN\$) | Number of options (in 000's) | Weighted average remaining contractual life (years) | Weighted average exercise price (CDN\$) |
|-------------------------------------|---------------------------------|---|---|
| 1.05 - 4.60 | 484 | 6.6 | 3.47 |
| 4.61 - 6.20 | 462 | 6.5 | 5.25 |
| 6.21 - 13.88 | 36 | 7.2 | 8.34 |
| | 982 | 6.6 | 4.48 |

During the quarter no stock options were exercised (three months ended June 30, 2017 – 103,215 stock options in exchange for 103,125 common shares). During the six months ended June 30, 2018, 375 stock options were exercised in exchange for 375 common shares (six months ended June 30, 2017 – 301,627 stock options in exchange for 214,499 common shares). The Company's SOP provides that an option holder may elect to receive a number of shares equivalent to the growth value of vested options, which is the difference between the market price and the exercise price of the options. The total cash consideration received by the Company for stock option exercises during the three months ended June 30, 2018 is nil (three months ended June 30, 2017 – \$197). The total cash consideration for received by the Company for stock option exercised for the six months ended June 30, 2018 was \$1 (six months ended June 30, 2017 - \$437).

The total stock option expense for the three months ended June 30, 2018 is \$144 (three months ended June 30, 2017 – recovery of \$258). The total stock option expense for the six months ended June 30, 2018 is \$228 (six months ended June 30, 2017 – recovery of \$117).

Cipher Pharmaceuticals Inc.

Notes to Interim Condensed Consolidated Financial Statements

June 30, 2018

(in thousands of United States dollars, except per share amounts - unaudited)

Restricted Share Unit (RSU) and Performance Share Unit (PSU) Plan

On May 13, 2015, the Company adopted a RSU and PSU plan. RSUs and PSUs are notional share units exchangeable for common shares of the Company. RSUs are granted to all employees and directors of the Company and PSUs are granted to certain executives. RSUs granted to employees vest annually over three or four years and RSUs granted to directors vest over a one year period. PSUs vest based upon the achievement of financial performance goals for the Company for the three years ended December 31, 2018. If certain targets are achieved, up to four times the PSU's granted will be exchanged for an equal number of common shares.

A summary of the RSUs and PSUs granted and outstanding as at June 30, 2018 is as follows:

| | RSU's Number of units | PSU's Number of units |
|---------------------------------------|--------------------------|--------------------------|
| | 000's | 000's |
| Balance, January 1, 2018 | 103 | 65 |
| Granted during the period | 151 | - |
| Vested during the period | (31) | (4) |
| Forfeited/cancelled during the period | (3) | (3) |
| Balance, June 30, 2018 | 220 | 58 |

The total expense for RSUs and PSUs for the three months ended June 30, 2018 is \$98 (three months ended June 30, 2017 – recovery of \$261). The total expense for the six months ended June 30, 2018 is \$166 (six months ended June 30, 2017 – recovery of \$153).

9. REVENUE

The Company earns licensing revenue from both royalties and product sales to its partners, the breakdown is as follows:

| | Three months ended June 30, 2018 | Three months ended June 30, 2017 | Six months ended June 30, 2018 | Six months ended June 30, 2017 |
|-------------------------|--|--|--------------------------------------|--------------------------------------|
| | \$ | \$ | \$ | \$ |
| | | Restated | | Restated |
| | | Note 2 | | Note 2 |
| Licensing revenue | | | | |
| Royalty revenue | 4,427 | 7,795 | 6,583 | 13,791 |
| Licensing product sales | 814 | 787 | 1,418 | 1,641 |
| Total licensing revenue | 5,241 | 8,582 | 8,001 | 15,432 |

10. EXPENSES BY NATURE

The consolidated statements of income (loss) and comprehensive income (loss) include the following expenses by nature:

| Employee salaries and benefits | Three months ended June 30, 2018 | Three months ended June 30, 2017 | Six months ended June 30, 2018 | Six months ended June 30, 2017 |
|--------------------------------------|--|--|--------------------------------------|--------------------------------------|
| | \$ | \$ | \$ | \$ |
| Salaries, bonuses and benefits | 948 | 875 | 2,002 | 1,678 |
| Share-based compensation | 245 | 28 | 403 | 238 |
| Termination benefits | (7) | 560 | 10 | 560 |
| Total employee salaries and benefits | 1,186 | 1,463 | 2,415 | 2,476 |

For the three and six months ended June 30, 2018 and June 30, 2017, all employee salaries and benefits are recorded in selling, general and administrative expenses.

Cipher Pharmaceuticals Inc.

Notes to Interim Condensed Consolidated Financial Statements

June 30, 2018

(in thousands of United States dollars, except per share amounts - unaudited)

11. COMPENSATION OF KEY MANAGEMENT

Key management includes directors and executives of the Company. The compensation paid or payable to key management for services is shown below:

| | Three months ended June 30, 2018 | Three months ended June 30, 2017 | Six months ended June 30, 2018 | Six months ended June 30, 2017 |
|--------------------------------|-------------------------------------|-------------------------------------|-----------------------------------|-----------------------------------|
| | \$ | \$ | \$ | \$ |
| Salaries, bonuses and benefits | 240 | 199 | 532 | 335 |
| Share-based compensation | 110 | (7) | 191 | 101 |
| Directors fees | 70 | 60 | 126 | 130 |
| Termination benefits | - | 265 | - | 265 |
| | 420 | 517 | 849 | 831 |

12. INCOME TAXES

Management uses estimates when determining current and deferred income taxes. These estimates are used to determine the recoverability of tax loss carry forward amounts, research and development expenditures and investment tax credits. Significant judgment is required regarding future probability of the Company to be able to realize deferred taxes. Changes in market conditions, changes in tax legislation, patent challenges and other factors, including the approval or launch of generic versions of any of the Company's products, could adversely affect the ongoing value of deferred taxes. The carrying amount of deferred income tax assets is reassessed at each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to utilize all or part of the deferred income tax assets. Unrecognized deferred income tax assets are reassessed at each reporting period and are recognized to the extent that it is probable that there will be sufficient taxable profits to allow all or part of the asset to be recovered.

Income tax expense is recognized based on the best estimate of the weighted average annual income tax rate expected for the full financial year.

The components of the income tax expense are as follows:

| | Three months ended June 30, 2018 | Three months ended June 30, 2017 | Six months ended June 30, 2018 | Six months ended June 30, 2017 |
|-----------------------------|-------------------------------------|-------------------------------------|-----------------------------------|-----------------------------------|
| | \$ | \$ | \$ | \$ |
| Current income tax expense | 294 | - | 244 | - |
| Deferred income tax expense | 633 | 1,225 | 542 | 944 |
| Income tax expense | 927 | 1,225 | 786 | 944 |

Income tax expense as reported differs from the amount that would be computed by applying the combined Canadian federal and provincial statutory income tax rates to income before income taxes. The reasons for the differences are as follows:

| | Three months ended June 30, 2018 | Three months ended June 30, 2017 | Six months ended June 30, 2018 | Six months ended June 30, 2017 |
|---|-------------------------------------|-------------------------------------|-----------------------------------|-----------------------------------|
| | \$ | \$ | \$ | \$ |
| Income before income taxes from continuing operations | 2,842 | 5,629 | 1,750 | 3,756 |
| Tax provision at the statutory income tax rate of 26.5% | 753 | 1,492 | 464 | 995 |
| Permanent differences | 102 | 97 | 90 | 387 |
| Effect of currency translation adjustment | 72 | (364) | 232 | (438) |
| Income tax expense | 927 | 1,225 | 786 | 944 |

Cipher Pharmaceuticals Inc.

Notes to Interim Condensed Consolidated Financial Statements

June 30, 2018

(in thousands of United States dollars, except per share amounts - unaudited)

The movement in the deferred income tax asset for the six months ended June 30, 2018 and 2017 is as follows:

| | Six months ended June 30, 2018 | Six months ended June 30, 2017 |
|------------------------------|-----------------------------------|-----------------------------------|
| | \$ | \$ |
| As at January 1 | 3,488 | 6,687 |
| Change in deferred tax asset | (542) | (942) |
| As at June 30 | 2,946 | 5,745 |

13. EARNINGS (LOSS) PER COMMON SHARE

Earnings (loss) per share is calculated using the weighted average number of common shares outstanding. The weighted average number of common shares outstanding for the three months ended June 30, 2018 was 26,767,803 (three months ended June 30, 2017 – 26,533,846). The weighted average number of shares outstanding for the six months ended June 30, 2018 was 26,749,751 (for the six months ended June 30, 2017 – 26,461,581).

Diluted earnings (loss) per common share is calculated using the weighted average number of common shares outstanding taking into consideration the weighted average impact of dilutive securities. The dilutive weighted average for the three months ended June 30, 2018 was 27,003,385 (three months ended June 30, 2017 – 26,778,894). The diluted weighted average number of shares outstanding for the six months ended June 30, 2018 was 26,886,843 (for the six months ended June 30, 2017 – 26,830,834).

14. COMMITMENTS AND CONTINGENCIES

In the normal course of business, the Company may be the subject of litigation or other potential claims. While management assesses the merits of each lawsuit and defends itself accordingly, the Company may be required to incur significant expenses or devote significant resources to defending itself against litigation. At June 30, 2018, no amounts were accrued (June 30, 2017 – nil).

Licensing Agreements with Galephar

In 2002, the Company entered into a Master Licensing and Clinical Supply Agreement ("the Agreement") with Galephar, a Puerto Rico based pharmaceutical research and manufacturing company. Under the Agreement, the Company acquired the rights to package, test, obtain regulatory approvals and market CIP-FENOFIBRATE, CIP-ISOTRETINOIN and CIP-TRAMADOL ER ("the CIP Products") in various countries. In accordance with the Agreement, the Company retains 50% of all revenue from licensing and distribution arrangements entered into with respect to the CIP Products, with the other 50% due to Galephar. Where the Company has opted to market and sell a CIP Product directly in a territory, the Company pays a royalty to Galephar. Galephar retains the right to manufacture and supply the CIP Products. With respect to licensing and distribution arrangements, the Company manages the product supply arrangements with their respective marketing partners and Galephar; product is shipped directly from Galephar to the respective marketing partners. Where the Company has opted to market and sell the CIP Product directly, the Company purchases the finished goods from Galephar directly.

With respect to CIP-ISOTRETINOIN, the Company has entered into licensing and distribution arrangements for the U.S., Mexico and Brazil, while opting to market and sell the product directly in Canada. The Company also has in place various licensing and distribution arrangements with respect to CIP-FENOFIBRATE in the U.S. and CIP-TRAMADOL ER in Canada, the U.S. and Latin America.

In 2016, Galephar entered into a contract with another party (the "Assignee") to assign certain rights relating to CIP-ISOTRETINOIN under the Agreement. The Company is a party to this contract, agreeing to remit revenue on the same terms as the Agreement, from licensing and distribution within the U.S. for CIP-ISOTRETOIN directly to the Assignee.

During the three and six months ended June 30, 2018, the Company paid Galephar \$1,026 (three months ended June 30, 2017 – \$924) and \$2,341 (six months ended June 30, 2017 – \$2,382), respectively. As at June 30, 2018, the amount in accounts payable and accrued liabilities owed to Galephar were \$3,054 (December 31, 2017 – \$3,296). Amounts payable to Galephar are remitted quarterly, after the Company collects from its licensing partners. Accordingly, the Company's accounts receivable has a corresponding balance representing amounts owed by its licensing partners.

Premise Lease

On July 19, 2018, the Company entered into an office lease agreement for its corporate operations to replace its current leased facility expiring December 31, 2018. The new office located in Oakville, Ontario will become the Company's new registered address. The term

Cipher Pharmaceuticals Inc.

Notes to Interim Condensed Consolidated Financial Statements

June 30, 2018

(in thousands of United States dollars, except per share amounts - unaudited)

of the lease is 10 years and 3 months, commencing on January 1, 2019. The total undiscounted commitment for the lease term is CDN\$4,328.

15. SEGMENTED INFORMATION

The Company's operations are categorized into one industry segment, being specialty pharmaceuticals. Prior to the disposal of the U.S. business, the Company managed its operations geographically in Canada and the United States, representing two segments. Following the disposal of the U.S. operations, the Company has one reportable segment.

The Company generated approximately 25% of its net revenue within Canada, with the remainder attributable to the U.S. There are no significant assets located outside of Canada.